CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a novel cancer immunotherapy that targets glycan-neoantigens, which are aberrantly expressed on cancer cells. By integrating glycobiology, immunology, and nanotechnology, it seeks to enhance immune recognition and therapeutic efficacy through engineered vaccines and T cells in mouse models.
Cancer remains a major cause of death despite phenomenal progress in current immunotherapy, that aims to boost host immune responses of antibodies and T cells, and their ability to distinguish cancer from normal cells.
The three main cancer immunotherapies are therapeutic cancer vaccines, cellular therapeutics and immune checkpoint blockade, but those have only limited success mainly due to difficulties in identifying target antigens.
Carbohydrate chains (glycans) ubiquitously occupy surface of…
TEL AVIV UNIVERSITY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
